Pharmaceutical - Cardio-vascular, GlaxoSmithKline

Filter

Popular Filters

GSK launches Phase III trial with losmapimod in acute coronary syndrome

GSK launches Phase III trial with losmapimod in acute coronary syndrome

06-06-2014

UK pharma major GlaxoSmithKline has announced the start of a pivotal Phase III study, LATITUDE-TIMI 60,…

Cardio-vascularCardiologyGlaxoSmithKlinelosmapimodPharmaceuticalResearchUK

Another disappointment for GlaxoSmithKline with darapladib

Another disappointment for GlaxoSmithKline with darapladib

13-05-2014

UK Pharma giant GlaxoSmithKline today announced disappointing headline results from its second Phase…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

GlaxoSmithKline’s darapladib flops in Ph III CHD trial

12-11-2013

UK pharma giant GlaxoSmithKline saw its shares dip 1.3% to £16.29 in mid-morning trading, after the…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

GlaxoSmithKline agrees £700 million deal with Aspen

GlaxoSmithKline agrees £700 million deal with Aspen

30-09-2013

GlaxoSmithKline says it has now reached agreement to sell its thrombosis brands, Arixtra and Fraxiparine,…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalRest of the World

US Appeals Court reverses 2012 decision on Lovaza, clearing way for generics

13-09-2013

Reversing a district court decision last year (The Pharma Letter May 30, 2012), the US Court of Appeals…

AmarinCardio-vascularGenericsGlaxoSmithKlineLegalLovazaNorth AmericaPar PharmaceuticalsPatentsPharmaceuticalTeva Pharmaceutical IndustriesVascepa

Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site

19-06-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday (June 18) that it has received an offer for…

ArixtraAspen PharmacareCardio-vascularFraxiparineGlaxoSmithKlineMergers & AcquisitionsPharmaceuticalProduction

US court rules in favor of Pronova/GlaxoSmithKline in Lovaza patent dispute

30-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) which has the marketing rights for Lovaza (omega-3-acid ethyl…

Cardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaPatentsPharmaceuticalPronova BioPharmaTeva Pharmaceutical Industries

EMA turns positive on orlistat and aprotinin; CHMP backs Pixuvri

20-02-2012

Finalizing its review on orlistat-containing medicines and the possible risk of severe liver injuries,…

AlliBayerBiotechnologyCardio-vascularCell TherapeuticsEuropeGlaxoSmithKlineMetabolicsOncologyorlistatPharmaceuticalPixuvriRegulationRocheTrasylolXenical

Back to top